Keep up to date with our latest partnering deals and highlights
Below is a selection of news releases describing recent deals completed by AstraZeneca and our biologics arm, MedImmune.
- Tuesday, 23 October 2012
- AstraZeneca and Ironwood announce linaclotide collaboration for China AstraZeneca and Ironwood Pharmaceuticals, Inc. announced today an agreement to co-develop and co-commercialise Ironwood’s linaclotide in China. Linaclotide is the first and only guanylate cyclase-C (GC-C) agonist approved by the US Food and Drug Administration, in August, for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC).
- Monday, 8 October 2012
- AstraZeneca and Ardelyx announce worldwide licensing deal for NHE3 Inhibitor Programme for complications of renal disease, including diabetes-induced renal disease AstraZeneca and Ardelyx today announced a worldwide exclusive licensing agreement for Ardelyx’s NHE3 inhibitor programme
- Wednesday, 26 September 2012
- AstraZeneca collaborates with Roche Diagnostics to advance personalised healthcare across therapeutic areas AstraZeneca today announced it has entered into a collaboration agreement with Roche Diagnostics